CLFX453X2201

• Research type

  Research Study

• Full title

  A randomized, vehicle controlled, active comparator, parallel group study to evaluate safety, tolerability and preliminary efficacy of topical LFX453 formulations in patients with actinic keratosis

• IRAS ID

  169855

• Contact name

  Mads Soerensen

• Contact email

  mads.soerensen@novartis.com

• Sponsor organisation

  Novartis Institutes for BioMedical Research (NIBR)

• Eudract number

  2014-003613-28

• Duration of Study in the UK

  1 years, 0 months, 4 days

• Research summary

  The purpose of the study is to characterize the safety, tolerability and efficacy profile of topical LFX453 formulations in patients with actinic keratosis to enable its further clinical development. This study will recruit patients with actinic keratosis(a disease of the skin) with the aim to evaluate the efficacy,the safety and the pharmacokinetics(way the body absorbs,distributes and gets rid of the drug)of LFX453 after multiple applications to the skin.

• REC name

  London - West London & GTAC Research Ethics Committee

• REC reference

  15/LO/0069

• Date of REC Opinion

  28 Jan 2015

• REC opinion

  Unfavourable Opinion